NASDAQ:DOVA - Dova Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Dova Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $28.04 0.00 (0.00 %) (As of 11/12/2019) Add Compare Today's Range$28.04Now: $28.04▼$28.0450-Day Range$27.97MA: $28.11▼$28.4052-Week Range$5.62Now: $28.04▼$28.54Volume35,036 shsAverage Volume499,313 shsMarket Capitalization$807.55 millionP/E RatioN/ADividend YieldN/ABeta2.74 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DOVA Previous Symbol CUSIPN/A CIK1685071 Webhttp://www.dova.com/ Phone919-748-5975Debt Debt-to-Equity Ratio0.41 Current Ratio5.64 Quick Ratio5.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10.35 million Price / Sales78.02 Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / Book10.35Profitability EPS (Most Recent Fiscal Year)($2.60) Net Income$-72,280,000.00 Net Margins-544.09% Return on Equity-101.60% Return on Assets-67.21%Miscellaneous Employees115 Outstanding Shares28,800,000Market Cap$807.55 million Next Earnings DateN/A OptionableOptionable Receive DOVA News and Ratings via Email Sign-up to receive the latest news and ratings for DOVA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:DOVA Rates by TradingView Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions What is Dova Pharmaceuticals' stock symbol? Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA." How were Dova Pharmaceuticals' earnings last quarter? Dova Pharmaceuticals Inc (NASDAQ:DOVA) announced its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by $0.03. The firm had revenue of $3.52 million for the quarter, compared to the consensus estimate of $5.63 million. Dova Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 544.09%. View Dova Pharmaceuticals' Earnings History. What price target have analysts set for DOVA? 6 brokerages have issued twelve-month price objectives for Dova Pharmaceuticals' shares. Their forecasts range from $15.00 to $30.00. On average, they expect Dova Pharmaceuticals' stock price to reach $26.42 in the next twelve months. This suggests that the stock has a possible downside of 5.8%. View Analyst Price Targets for Dova Pharmaceuticals. What is the consensus analysts' recommendation for Dova Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dova Pharmaceuticals. Has Dova Pharmaceuticals been receiving favorable news coverage? News coverage about DOVA stock has trended positive recently, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dova Pharmaceuticals earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Dova Pharmaceuticals. Are investors shorting Dova Pharmaceuticals? Dova Pharmaceuticals saw a drop in short interest in November. As of November 15th, there was short interest totalling 572,700 shares, a drop of 51.9% from the October 31st total of 1,190,000 shares. Based on an average trading volume of 587,400 shares, the days-to-cover ratio is presently 1.0 days. Approximately 4.4% of the shares of the stock are sold short. View Dova Pharmaceuticals' Current Options Chain. Who are some of Dova Pharmaceuticals' key competitors? Some companies that are related to Dova Pharmaceuticals include HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH), Myokardia (MYOK), PTC Therapeutics (PTCT), Genmab A/S (GMAB), Uniqure (QURE), Biohaven Pharmaceutical (BHVN), Emergent Biosolutions (EBS), Deciphera Pharmaceuticals (DCPH), Amicus Therapeutics (FOLD), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Agios Pharmaceuticals (AGIO), Arena Pharmaceuticals (ARNA) and Xencor (XNCR). What other stocks do shareholders of Dova Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dova Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Sasol (SSL), Aldeyra Therapeutics (ALDX), Fate Therapeutics (FATE), Heron Therapeutics (HRTX), TESARO (TSRO), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX) and Allena Pharmaceuticals (ALNA). Who are Dova Pharmaceuticals' key executives? Dova Pharmaceuticals' management team includes the folowing people: Dr. David S. Zaccardelli, Pres & CEO (Age 54)Mr. Mark W. Hahn, CFO & Sec. (Age 56)Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 41)Mr. Jason Levine, VP of MarketingMr. Ilija Zlatar, Head of U.S. Sales When did Dova Pharmaceuticals IPO? (DOVA) raised $66 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 4,100,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO. Who are Dova Pharmaceuticals' major shareholders? Dova Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include GW&K Investment Management LLC (1.15%), State Street Corp (0.66%), Gabelli Funds LLC (0.26%), Millennium Management LLC (0.18%), GABELLI & Co INVESTMENT ADVISERS INC. (0.11%) and Virtu Financial LLC (0.07%). Company insiders that own Dova Pharmaceuticals stock include Alex Sapir, David Zaccardelli, Jason Hoitt, Kevin Laliberte, Lee F Md Phd Allen, Life Sciences Maste Perceptive, Mark W Hahn, Paul B Manning, Roger Jeffs and Steven M Goldman. View Institutional Ownership Trends for Dova Pharmaceuticals. Which major investors are selling Dova Pharmaceuticals stock? DOVA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Street Corp and Barclays PLC. Company insiders that have sold Dova Pharmaceuticals company stock in the last year include David Zaccardelli, Jason Hoitt, Kevin Laliberte, Lee F Md Phd Allen, Mark W Hahn and Roger Jeffs. View Insider Buying and Selling for Dova Pharmaceuticals. Which major investors are buying Dova Pharmaceuticals stock? DOVA stock was purchased by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Gabelli Funds LLC, GABELLI & Co INVESTMENT ADVISERS INC., Virtu Financial LLC, Tower Research Capital LLC TRC and Meeder Asset Management Inc.. Company insiders that have bought Dova Pharmaceuticals stock in the last two years include Alex Sapir, David Zaccardelli, Life Sciences Maste Perceptive, Paul B Manning and Steven M Goldman. View Insider Buying and Selling for Dova Pharmaceuticals. How do I buy shares of Dova Pharmaceuticals? Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Dova Pharmaceuticals' stock price today? One share of DOVA stock can currently be purchased for approximately $28.04. How big of a company is Dova Pharmaceuticals? Dova Pharmaceuticals has a market capitalization of $807.55 million and generates $10.35 million in revenue each year. The company earns $-72,280,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Dova Pharmaceuticals employs 115 workers across the globe.View Additional Information About Dova Pharmaceuticals. What is Dova Pharmaceuticals' official website? The official website for Dova Pharmaceuticals is http://www.dova.com/. How can I contact Dova Pharmaceuticals? Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected] MarketBeat Community Rating for Dova Pharmaceuticals (NASDAQ DOVA)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 206 (Vote Outperform)Underperform Votes: 206 (Vote Underperform)Total Votes: 412MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote "Outperform" if you believe DOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DOVA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/6/2019 by MarketBeat.com StaffFeatured Article: Understanding Options Trading